INVO Fertility appoints WithumSmith+Brown as new auditor after dismissal of M&K CPAS

INVO Fertility, Inc. (NASDAQ:IVF) announced Friday that its board’s audit committee approved the dismissal of M&K CPAS, PLLC as the company’s independent registered public accounting firm, effective Friday. The company also reported the appointment of WithumSmith+Brown, PC as its new independent registered public accounting firm, effective immediately, to audit INVO Fertility’s consolidated financial statements for the year ending December 31, 2025.

According to a statement in the SEC filing, M&K CPAS’s audit reports for the fiscal years ended December 31, 2023 and December 31, 2024 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified as to uncertainty, audit scope, or accounting principles. However, the reports included an expression of substantial doubt about INVO Fertility’s ability to continue as a going concern.

The company stated that during the two most recent fiscal years and the subsequent interim period through Friday, there were no disagreements between INVO Fertility and M&K CPAS on accounting principles, financial statement disclosure, or auditing scope or procedures that would have required disclosure. There were also no reportable events as defined by SEC regulations.

INVO Fertility also confirmed that, prior to the engagement, neither the company nor anyone acting on its behalf had consulted WithumSmith+Brown regarding the application of accounting principles to a specific transaction or the type of audit opinion that might be rendered on the company’s financial statements. There were no discussions with WithumSmith+Brown about any accounting, auditing, or financial reporting issues, nor were there any disagreements or reportable events.

The information in this article is based on a statement provided in the company’s Form 8-K filing with the Securities and Exchange Commission.

In other recent news, INVO Fertility announced the issuance of $200,000 in Series C-2 preferred stock to an institutional investor. This transaction, which took place on July 28, 2025, involved the investor exercising its Additional Investment Right to acquire 200 shares. The company also revealed a 1-for-3 reverse stock split, effective July 21, 2025, which will see its common stock continue trading under the same symbol but with a new CUSIP number. Additionally, INVO Fertility amended its preferred stock agreements, allowing holders to purchase additional Series C-2 Preferred shares through cash or exchange. The company also adjourned its annual shareholder meeting, rescheduling it to July 23, 2025, after initially adjourning it to address an outstanding proposal. At the rescheduled meeting, stockholders approved key proposals, including the election of five board nominees. These developments highlight INVO Fertility’s ongoing adjustments in its capital structure and governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.